


ARN-3236

Cat. No.:	HY-120856		
CAS No.:	1613710-01-2		
Molecular Formula:	C ₁₉ H ₁₆ N ₂ O ₂ S		
Molecular Weight:	336.41		
Target:	Salt-inducible Kinase (SIK)		
Pathway:	Immunology/Inflammation		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



Solvent & Solubility

In Vitro	DMSO : 130 mg/mL (386.43 mM; Need ultrasonic)					
		Solvent Concentration	Mass	1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.9726 mL	14.8628 mL	29.7256 mL	
		5 mM	0.5945 mL	2.9726 mL	5.9451 mL	
		10 mM	0.2973 mL	1.4863 mL	2.9726 mL	
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.17 mg/mL (6.45 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.17 mg/mL (6.45 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.17 mg/mL (6.45 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	ARN-3236 is an oral active and selective inhibitor of salt-inducible kinase 2 (SIK2) , with IC ₅₀ s of <1 nM, 21.63 nM and 6.63 nM for SIK2, SIK1 and SIK3, respectively. Has anti-cancer activity ^{[1][2]} .		
IC ₅₀ & Target	SIK2 <1 nM (IC ₅₀)	SIK1 21.63 nM (IC ₅₀)	SIK3 6.63 nM (IC ₅₀)

REFERENCES

- [1]. Lombardi MS, et al. SIK inhibition in human myeloid cells modulates TLR and IL-1R signaling and induces an anti-inflammatory phenotype. J Leukoc Biol. 2016 May;99(5):711-21.
- [2]. Zhou J, et al. A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts. Clin Cancer Res. 2017 Apr 15;23(8):1945-1954.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA